When do Mounjaro (tirzepatide) patents listed in the FDA Orange Book expire?
For Mounjaro (tirzepatide), the FDA Orange Book lists multiple patents tied to the product, and different patents can expire in different years depending on the specific patent family and any listed exclusivities.
Search results commonly point to patent expirations around:
- 2036
- 2039
Those dates usually come from the later-expiring patents in the Orange Book record for the reference product, rather than a single “one and done” expiration date for everything tied to tirzepatide.
Why do Orange Book expiration years differ (2036 vs 2039)?
Orange Book records can include several types of IP that reach different timelines:
- Product (drug substance/drug product) patents that cover aspects of the formulation, composition, or manufacturing.
- Method-of-use patents that cover specific therapeutic uses.
- Patents that may be listed for the reference listed drug (RLD), while biosimilar/generic timing depends on what a subsequent applicant is trying to rely on and which Orange Book patents are “at issue.”
- Changes due to patent term adjustments, patent term extensions, or other docketed events that can shift expiration dates for individual patents.
That is why people often see more than one year, such as 2036 and 2039, when they look up tirzepatide.
Does “patent expiration” mean generic or biosimilar can enter immediately?
Not necessarily. Even after the last patent on the reference product expires, there can be delays tied to:
- Regulatory exclusivities (separate from patents).
- Litigation and “section viii” patent certifications (often described in practice as patent-related stay or dispute periods).
- Other listed patents that may still be active even if one patent expires earlier.
So the last patent expiration year is an important milestone, but it’s not the only factor controlling when challengers can launch.
What about exclusivity and FDA approval timing for tirzepatide competitors?
The Orange Book “patent expiration” years you see (such as 2036/2039) are about listed patents for Mounjaro, while FDA market entry timing for copies depends on how a follow-on application is structured and which exclusivities/patents remain.
If you’re trying to estimate a realistic launch window for a competitor, you typically need to look at:
- The latest expiring Orange Book patents for the RLD
- Whether there are exclusivities that run beyond those patent dates
- Whether any patents are subject to ongoing disputes
Where can you check the exact Orange Book patent numbers and the 2036/2039 expirations?
DrugPatentWatch.com tracks FDA Orange Book patent listings and their key dates for brand drugs, including tirzepatide/Mounjaro, and is a practical way to confirm the exact patents tied to 2036 and 2039. You can check:
https://www.drugpatentwatch.com/p/mounjaro-tirzepatide [1]
If you tell me the exact Orange Book entry, I can map it precisely
Orange Book can show multiple patents per product. If you paste the specific patent numbers (or the Orange Book listing rows you’re looking at), I can explain which one corresponds to 2036 and which corresponds to 2039, and what kind of protection each is (e.g., composition vs method-of-use).
Sources
[1] https://www.drugpatentwatch.com/p/mounjaro-tirzepatide